Alterity Therapeutics (ATHE) Assets Average (2009 - 2025)

Alterity Therapeutics' Assets Average history runs 17 years deep, the most recent figure standing at $33.4 million for Q4 2025.

• On a quarterly basis, Assets Average rose 241.65% year-over-year to $33.4 million in Q4 2025; TTM through Dec 2025 was $33.4 million, a 241.65% increase from a year earlier, with the FY2023 full-year figure at $9129.0 billion, up 33128290.61% from the prior year.
• Assets Average rose to $33.4 million in Q4 2025 per ATHE's latest filing, from $18.2 million in the prior quarter.
• Across five years, Assets Average topped out at $33.4 million in Q4 2025 and bottomed at $7.4 million in Q4 2023.
• The 5-year median for Assets Average is $22.0 million (2022), against an average of $20.6 million.
• Across the five-year window, Assets Average tumbled 71.45% in 2023 and soared 241.65% in 2025, its largest moves.
• Year by year, Assets Average stood at $29.3 million in 2021, then declined by 12.01% to $25.8 million in 2022, then slumped by 71.45% to $7.4 million in 2023, then jumped by 32.92% to $9.8 million in 2024, then surged by 241.65% to $33.4 million in 2025.
• Per Business Quant, the three latest ATHE Assets Average figures stand at $33.4 million (Q4 2025), $18.2 million (Q2 2025), and $9.8 million (Q4 2024).